Owing to the activity of gemcitabine, a variety of studies have now assessed its activity in combination with other chemotherapy or novel agents.
In view of the synergy between these two drugs and the manageable toxicity of the combination, this trial was undertaken to assess its activity in oesophageal carcinoma.
To verify this, we immunoprecipitated endogenous WNK1 and WNK3 from wild-type and knockin ES cells and assessed its activity by monitoring its ability to phosphorylate OSR1 in vitro.
This present phase II study proposes FIr-B/FOx or "Poker" association (so called because it represents the combination of four drugs), adding Bevacizumab to this triplet chemotherapeutic schedule, in order to assess its activity, efficacy and safety.
Erlotinib (Tarceva™, OSI-774), a potent epidermal growth factor receptor tyrosine kinase inhibitor (EGFR), was evaluated in a phase II study to assess its activity in patients with metastatic colorectal cancer.
Herein, we analysed ALK mRNA expression, copy number variation, and mutational status in RMS, with clinical and molecular correlation in a cohort of 87 patients, and assessed its activity in vitro.
We therefore subjected tumour-bearing RT2 mice to the local delivery of affinity-purified Uncl-Sema3E (see Supporting Information Fig 8) into the pancreas by means of Alzet osmotic mini-pumps, in order to assess its activity in inhibiting angiogenesis and regressing tumour burden.
